A potential sleep-modulating effect of A2 milk-derived casein hydrolysate containing opioid peptide CM-12: A randomized placebo-controlled crossover pilot trial

Authors:
  • YCYingjie Cui
    Yingjie Cui
  • NSNaoko Suzuki
    Naoko Suzuki
  • YKYuki Kamioka
    Yuki Kamioka
  • TITomoya Isaji
    Tomoya Isaji
  • TNTakeshi Nakaoka
    Takeshi Nakaoka
  • SWShin Watanabe
    Shin Watanabe
  • NHNobuhiro Hayashi
    Nobuhiro Hayashi

Abstract
Milk‐derived bioactive peptides that influence sleep quality are emerging as promising functional food ingredients in today’s increasingly stressful society. Insufficient sleep is a growing health concern, for which food-derived bioactive peptides have emerged as potential modulators of sleep quality. CM-12, an A2 milk-derived opioid peptide produced using the Aspergillus oryzae protease Alp, has been shown to have anxiolytic activity in mice. We evaluated the effects of CM-12 casein hydrolysate in adults with poor sleep quality. Objective sleep parameters were assessed using a non-contact sleep mat, and subjective outcomes were evaluated using the OSA-MA and a questionnaire. Among 22 participants completing both intervention phases, CM-12 casein hydrolysate supplementation showed trends toward a shorter sleep-onset latency, greater sleep efficiency, and lower arousal, but no significant difference between CM-12 and placebo groups. However, stress‐stratified analysis revealed that participants experiencing lower treatment‐related stress showed significant increases in total sleep time with CM‐12. No adverse events or clinically relevant abnormalities were observed. These findings provide the first clinical evidence suggesting that CM-12 casein hydrolysate may contribute to sleep initiation and nocturnal stability, thus warranting confirmation in larger trials for commercial use.